GL Pharm Tech Balance Sheet Health
Financial Health criteria checks 5/6
GL Pharm Tech has a total shareholder equity of ₩12.3B and total debt of ₩17.6B, which brings its debt-to-equity ratio to 143.5%. Its total assets and total liabilities are ₩39.9B and ₩27.6B respectively.
Key information
143.5%
Debt to equity ratio
₩17.63b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩4.14b |
| Equity | ₩12.28b |
| Total liabilities | ₩27.59b |
| Total assets | ₩39.87b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A204840's short term assets (₩16.6B) exceed its short term liabilities (₩12.3B).
Long Term Liabilities: A204840's short term assets (₩16.6B) exceed its long term liabilities (₩15.3B).
Debt to Equity History and Analysis
Debt Level: A204840's net debt to equity ratio (109.8%) is considered high.
Reducing Debt: A204840's debt to equity ratio has reduced from 195.2% to 143.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A204840 has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: A204840 is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.